加拿大安大略省新冠肺炎大流行期间的Indolent淋巴瘤护理提供和结果。

IF 5.1 2区 医学 Q1 HEMATOLOGY British Journal of Haematology Pub Date : 2023-10-27 DOI:10.1111/bjh.19166
Inna Y. Gong, Anca Prica, Zharmaine Ante, Andrew Calzavara, Monika K. Krzyzanowska, Simron Singh, Adam Suleman, Matthew C. Cheung, Michael Crump
{"title":"加拿大安大略省新冠肺炎大流行期间的Indolent淋巴瘤护理提供和结果。","authors":"Inna Y. Gong,&nbsp;Anca Prica,&nbsp;Zharmaine Ante,&nbsp;Andrew Calzavara,&nbsp;Monika K. Krzyzanowska,&nbsp;Simron Singh,&nbsp;Adam Suleman,&nbsp;Matthew C. Cheung,&nbsp;Michael Crump","doi":"10.1111/bjh.19166","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The treatment pattern and outcomes in patients with indolent B-cell lymphoma treated during the coronavirus disease 2019 (COVID-19) pandemic period compared to the prepandemic period are unclear. This was a retrospective population-based study using administrative databases in Ontario, Canada (follow-up to 31 March 2022). The primary outcome was treatment pattern; secondary outcomes were death, toxicities, healthcare utilization (emergency department [ED] visit, hospitalization) and SARS-CoV-2 outcomes. Adjusted hazard ratios (aHR) from Cox proportional hazards models were used to estimate associations. We identified 4143 patients (1079 pandemic, 3064 prepandemic), with a median age of 69 years. In both time periods, bendamustine (B) + rituximab (BR) was the most frequently prescribed regimen. During the pandemic, fewer patients received R maintenance or completed the full 2-year course (aHR 0.81, 95% CI 0.71–0.92, <i>p</i> = 0.001). Patients treated during the pandemic had less healthcare utilization (ED visit aHR 0.77, 95% CI 0.68, 0.88, <i>p</i> &lt; 0.0001; hospitalization aHR 0.81, 95% CI 0.70–0.94, <i>p</i> = 0.0067) and complications (infection aHR 0.69, 95% CI 0.57–0.82, <i>p</i> &lt; 0.0001; febrile neutropenia aHR 0.66, 95% CI 0.47–0.94, <i>p</i> = 0.020), with no difference in death. Independent of vaccination, active rituximab use was associated with a higher risk of COVID-19 complications. Despite similar front-line regimen use, healthcare utilization and admissions for infection were <i>less</i> in the pandemic cohort.</p>\n </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"204 3","pages":"805-814"},"PeriodicalIF":5.1000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada\",\"authors\":\"Inna Y. Gong,&nbsp;Anca Prica,&nbsp;Zharmaine Ante,&nbsp;Andrew Calzavara,&nbsp;Monika K. Krzyzanowska,&nbsp;Simron Singh,&nbsp;Adam Suleman,&nbsp;Matthew C. Cheung,&nbsp;Michael Crump\",\"doi\":\"10.1111/bjh.19166\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>The treatment pattern and outcomes in patients with indolent B-cell lymphoma treated during the coronavirus disease 2019 (COVID-19) pandemic period compared to the prepandemic period are unclear. This was a retrospective population-based study using administrative databases in Ontario, Canada (follow-up to 31 March 2022). The primary outcome was treatment pattern; secondary outcomes were death, toxicities, healthcare utilization (emergency department [ED] visit, hospitalization) and SARS-CoV-2 outcomes. Adjusted hazard ratios (aHR) from Cox proportional hazards models were used to estimate associations. We identified 4143 patients (1079 pandemic, 3064 prepandemic), with a median age of 69 years. In both time periods, bendamustine (B) + rituximab (BR) was the most frequently prescribed regimen. During the pandemic, fewer patients received R maintenance or completed the full 2-year course (aHR 0.81, 95% CI 0.71–0.92, <i>p</i> = 0.001). Patients treated during the pandemic had less healthcare utilization (ED visit aHR 0.77, 95% CI 0.68, 0.88, <i>p</i> &lt; 0.0001; hospitalization aHR 0.81, 95% CI 0.70–0.94, <i>p</i> = 0.0067) and complications (infection aHR 0.69, 95% CI 0.57–0.82, <i>p</i> &lt; 0.0001; febrile neutropenia aHR 0.66, 95% CI 0.47–0.94, <i>p</i> = 0.020), with no difference in death. Independent of vaccination, active rituximab use was associated with a higher risk of COVID-19 complications. Despite similar front-line regimen use, healthcare utilization and admissions for infection were <i>less</i> in the pandemic cohort.</p>\\n </div>\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":\"204 3\",\"pages\":\"805-814\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2023-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19166\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19166","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

2019冠状病毒病(新冠肺炎)大流行期间接受治疗的惰性B细胞淋巴瘤患者的治疗模式和结果与大流行前相比尚不清楚。这是一项使用加拿大安大略省行政数据库进行的基于人群的回顾性研究(随访至2022年3月31日)。主要结果是治疗模式;次要结果是死亡、毒性、医疗利用率(急诊就诊、住院)和严重急性呼吸系统综合征冠状病毒2型结果。Cox比例风险模型的调整后风险比(aHR)用于估计关联。我们确定了4143名患者(1079名大流行患者,3064名大流行前患者),中位年龄为69岁 年。在这两个时间段内,苯达莫司汀(B) + 利妥昔单抗(BR)是最常见的处方方案。在疫情期间,接受R维持或完成2年疗程的患者较少(aHR 0.81,95%CI 0.71-0.92,p = 0.001)。在大流行期间接受治疗的患者的医疗保健利用率较低(ED访视aHR 0.77,95%CI 0.68,0.88,p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada

The treatment pattern and outcomes in patients with indolent B-cell lymphoma treated during the coronavirus disease 2019 (COVID-19) pandemic period compared to the prepandemic period are unclear. This was a retrospective population-based study using administrative databases in Ontario, Canada (follow-up to 31 March 2022). The primary outcome was treatment pattern; secondary outcomes were death, toxicities, healthcare utilization (emergency department [ED] visit, hospitalization) and SARS-CoV-2 outcomes. Adjusted hazard ratios (aHR) from Cox proportional hazards models were used to estimate associations. We identified 4143 patients (1079 pandemic, 3064 prepandemic), with a median age of 69 years. In both time periods, bendamustine (B) + rituximab (BR) was the most frequently prescribed regimen. During the pandemic, fewer patients received R maintenance or completed the full 2-year course (aHR 0.81, 95% CI 0.71–0.92, p = 0.001). Patients treated during the pandemic had less healthcare utilization (ED visit aHR 0.77, 95% CI 0.68, 0.88, p < 0.0001; hospitalization aHR 0.81, 95% CI 0.70–0.94, p = 0.0067) and complications (infection aHR 0.69, 95% CI 0.57–0.82, p < 0.0001; febrile neutropenia aHR 0.66, 95% CI 0.47–0.94, p = 0.020), with no difference in death. Independent of vaccination, active rituximab use was associated with a higher risk of COVID-19 complications. Despite similar front-line regimen use, healthcare utilization and admissions for infection were less in the pandemic cohort.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.60
自引率
4.60%
发文量
565
审稿时长
1 months
期刊介绍: The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
期刊最新文献
Depression, sleep and pain affect instrumental activities of daily living through cognitive functioning in adults with sickle cell disease: A report from the Sickle Cell Disease Implementation Consortium. Are we there yet? CAR-T therapy in multiple myeloma. Rates of discordant CD20 status by flow cytometry and immunohistochemistry in B-ALL. EBV-positive inflammatory follicular dendritic cell sarcoma, an entity by many names. Impaired physical ability in patients with transfusion-dependent β-thalassaemia: Can regular physical activity be a countermeasure?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1